Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by RTW Investments LP

RTW Investments LP raised its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 28.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,600,799 shares of the company’s stock after purchasing an additional 1,008,813 shares during the period. Protagonist Therapeutics accounts for approximately 2.2% of RTW Investments LP’s holdings, making the stock its 17th biggest position. RTW Investments LP owned approximately 0.08% of Protagonist Therapeutics worth $105,818,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Quantbot Technologies LP acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter worth approximately $76,000. Jane Street Group LLC lifted its stake in shares of Protagonist Therapeutics by 273.3% in the 3rd quarter. Jane Street Group LLC now owns 10,289 shares of the company’s stock worth $87,000 after acquiring an additional 7,533 shares during the period. Ensign Peak Advisors Inc lifted its stake in shares of Protagonist Therapeutics by 14.9% in the 3rd quarter. Ensign Peak Advisors Inc now owns 12,270 shares of the company’s stock worth $103,000 after acquiring an additional 1,590 shares during the period. Alpine Global Management LLC acquired a new stake in shares of Protagonist Therapeutics in the 4th quarter worth approximately $112,000. Finally, Arizona State Retirement System acquired a new stake in shares of Protagonist Therapeutics in the 4th quarter worth approximately $113,000. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Trading Up 1.5 %

Shares of NASDAQ PTGX traded up $0.29 during midday trading on Friday, reaching $19.05. The company’s stock had a trading volume of 445,433 shares, compared to its average volume of 507,943. The company has a 50 day moving average price of $20.00 and a 200 day moving average price of $22.40. Protagonist Therapeutics, Inc. has a one year low of $7.24 and a one year high of $30.10. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -7.11 and a beta of 1.86.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.03). Research analysts anticipate that Protagonist Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PTGX. JMP Securities upped their price target on shares of Protagonist Therapeutics from $28.00 to $35.00 in a research note on Thursday, July 6th. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Protagonist Therapeutics in a report on Friday, August 4th. Finally, StockNews.com assumed coverage on shares of Protagonist Therapeutics in a report on Thursday, August 17th. They issued a “sell” rating on the stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease.